Development and Validation of a Nomogram to Predict the Recurrence of HCC Patients Undergoing CECT After Ablation

References

• Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314. doi:10.1016/j.bbcan.2019.188314
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• European association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181–223. doi:10.1159/000514174
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatol. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Izzo F, Granata V, Grassi R, et al. Radiofrequency ablation and microwave ablation in liver tumors: an update. Oncologist. 2019;24(10):e990–e1005. doi:10.1634/theoncologist.2018-0337
   PubMed Web of Science ®Google Scholar
• Kim JW, Shin SS, Heo SH, et al. Ultrasound-guided percutaneous radiofrequency ablation of liver tumors: how we do it safely and completely. Korean J Radiol. 2015;16(6):1226–1239. doi:10.3348/kjr.2015.16.6.1226
   PubMed Web of Science ®Google Scholar
• Ahmed M, Kumar G, Moussa M, et al. Hepatic radiofrequency ablation-induced stimulation of distant tumor growth is suppressed by c-met inhibition. Radiology. 2016;279(1):103–117. doi:10.1148/radiol.2015150080
   PubMed Web of Science ®Google Scholar
• Ruzzenente A, Manzoni GD, Molfetta M, et al. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World J Gastroenterol. 2004;10(8):1137–1140. doi:10.3748/wjg.v10.i8.1137
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Nikfarjam M, Muralidharan V, Christophi C. Mechanisms of focal heat destruction of liver tumors. J Surg Res. 2005;127(2):208–223. doi:10.1016/j.jss.2005.02.009
   PubMed Web of Science ®Google Scholar
• Wu D, Yang Y, Chen J, Cai H, Duan Y, Sun D. Three different ways of treating primary hepatocellular carcinoma at an early stage: a prospective comparative study. Gastroenterol Res Pract. 2020;2020:7802498. doi:10.1155/2020/7802498
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Jang JY, Kim MY, Jeong SW, et al. Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions. Clinic Molec Hepatol Mar. 2013;19(1):1–16. doi:10.3350/cmh.2013.19.1.1
   PubMedGoogle Scholar
• Vestito A, Dajti E, Cortellini F, Montagnani M, Bazzoli F, Zagari RM. Can liver ultrasound elastography predict the risk of hepatocellular carcinoma recurrence after radiofrequency ablation? A systematic review and Meta-Analysis. Ultraschall Med. 2023;44(3):e139–e147. doi:10.1055/a-1657-8825
   PubMedGoogle Scholar
• Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatol. 2023;78(6):1922–1965. doi:10.1097/HEP.0000000000000466
   PubMedGoogle Scholar
• Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398(10308):1359–1376. doi:10.1016/S0140-6736(21)01374-X
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526–549. doi:10.1016/j.jhep.2017.09.016
   PubMed Web of Science ®Google Scholar
• Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875. doi:10.3390/cells9040875
   PubMed Web of Science ®Google Scholar
• Jung KS, Kim SU, Choi GH, et al. Prediction of recurrence after curative resection of hepatocellular carcinoma using liver stiffness measurement (fibroscan®). Ann Surg Oncol. 2012;19(13):4278–4286. doi:10.1245/s10434-012-2422-3
   PubMed Web of Science ®Google Scholar
• Yang Y, Xin Y, Ye F, et al. Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors. Int J Hyperthermia. 2021;38(1):437–446. doi:10.1080/02656736.2020.1849828
   PubMed Web of Science ®Google Scholar
• Hanigan MH. Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Adv Cancer Res. 2014;122:103–141. doi:10.1016/b978-0-12-420117-0.00003-7
   PubMed Web of Science ®Google Scholar
• Lei Z, Li J, Wu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis b virus-related hepatocellular carcinoma within the Milan criteria. JAMA Surgery. 2016;151(4):356–363. doi:10.1001/jamasurg.2015.4257
   PubMed Web of Science ®Google Scholar
• Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surgery. 2019;154(3):209–217. doi:10.1001/jamasurg.2018.4334
   PubMed Web of Science ®Google Scholar
• Zhang SW, Zhang NN, Zhu WW, et al. A novel nomogram model to predict the recurrence-free survival and overall survival of hepatocellular carcinoma. Front Oncol. 2022;12:946531. doi:10.3389/fonc.2022.946531
   PubMedGoogle Scholar
• M-c H, Hasegawa K, Chen X-P, et al. Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-pacific primary liver cancer expert meeting (APPLE 2014). Liver Cancer. 2016;5(4):245–256. doi:10.1159/000449336
   PubMed Web of Science ®Google Scholar
• Deng Y, Pang Q, Miao R-C, et al. Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma. Onco Targets Ther. 2016;9:5317–5328. doi:10.2147/OTT.S109736
   PubMed Web of Science ®Google Scholar
• Wang S, Deng Y, Yu X, et al. Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram. Sci Rep. 2021;11(1):13814. doi:10.1038/s41598-021-93289-3
   PubMed Web of Science ®Google Scholar
• Li J, Li Z, Hao S, et al. Inversed albumin-to-globulin ratio and underlying liver disease severity as a prognostic factor for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Diagn Interv Radiol. 2023;29(3):520–528. doi:10.5152/dir.2022.211166
   PubMed Web of Science ®Google Scholar
• Ikeda M, Arai Y, Inaba Y, et al. Conventional or drug-eluting beads? Randomized controlled study of chemoembolization for hepatocellular carcinoma: JIVROSG-1302. Liver Cancer. 2022;11(5):440–450. doi:10.1159/000525500
   PubMed Web of Science ®Google Scholar
• Raoul J-L, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. doi:10.1016/j.ctrv.2018.11.002
   PubMed Web of Science ®Google Scholar
• Deng M, Li S-H, Guo R-P. Recent advances in local thermal ablation therapy for hepatocellular carcinoma. Am Surg. 2023;89(5):1966–1973. doi:10.1177/00031348211054532
   PubMed Web of Science ®Google Scholar
• Kloeckner R, Galle PR, Bruix J. Local and regional therapies for hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):137–149. doi:10.1002/hep.31424
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Chen MS, Chen Y, Lau WY, Peng Z. Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma. JAMA network open. 2021;4(9):e2126992. doi:10.1001/jamanetworkopen.2021.26992
   PubMed Web of Science ®Google Scholar
• Wang Q, Qiao W, Zhang H, et al. Nomogram established on account of lasso-cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol. 2022;13:1019638. doi:10.3389/fimmu.2022.1019638
   PubMed Web of Science ®Google Scholar